If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Frontotemporal dementia (FTD) is a rare and progressive form of dementia that primarily affects people between the ages of 40 ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Sleep has been shown to have a long list of physical and mental health benefits, and now a new study suggests it could also ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

But many people who take daily medications are unaware that certain drugs in their pill box can also increase their risk of ...

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...